NCT00587457 is a Phase 1 clinical trial of CAT-8015 5 mcg/kg in Leukemia, Lymphoma, Chronic Lymphocytic, sponsored by MedImmune LLC.

Who is sponsoring NCT00587457?

NCT00587457 is sponsored by MedImmune LLC.

What drugs are being tested in NCT00587457?

Interventions in NCT00587457: CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg.

What condition does NCT00587457 study?

NCT00587457 studies Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox.

Is NCT00587457 still recruiting?

NCT00587457 is currently terminated. Last updated 6 July 2017.

Are results published for NCT00587457?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-07-06 · How we verify

NCT00587457

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Terminated Phase 1 Results posted Last updated 6 July 2017

What this trial tests

Phase 1 trial testing CAT-8015 5 mcg/kg in Leukemia, Lymphoma, Chronic Lymphocytic in 11 participants. Terminated before completion.

Timeline

7 March 2007

Primary endpoint
7 April 2008

7 April 2008

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	7 March 2007
Primary completion	7 April 2008
Estimated completion	7 April 2008
Sites	3 locations across United States, Poland

Drugs / interventions tested

CAT-8015 5 mcg/kg — full drug profile →
CAT-8015 10 mcg/kg — full drug profile →
CAT-8015 20 mcg/kg — full drug profile →

Conditions studied

Leukemia, Lymphoma, Chronic Lymphocytic — all drugs for Leukemia, Lymphoma, Chronic Lymphocytic →
Leukemia, Prolymphocytic Leukemia, Small — all drugs for Leukemia, Prolymphocytic Leukemia, Small →
Lymphocytic Lymphoma, Moxetumomab Pasudotox — all drugs for Lymphocytic Lymphoma, Moxetumomab Pasudotox →

Sponsor

MedImmune LLC — full company profile →

Who can join

18 and older, any sex, with Leukemia, Lymphoma, Chronic Lymphocytic or Leukemia, Prolymphocytic Leukemia, Small. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) Primary · From start of study drug administration until 30 days after the last dose of study drug

An adverse event (AE) events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug, for the period extending to 30 days after the last dose of study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offs

TEAEs

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	3
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	3
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	5

TESAEs

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	2
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	3

Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs) Primary · From start of study drug administration until 30 days after the last dose of study drug

The vital sign abnormalities which require an action or intervention by the investigator, or a finding judged by the investigator were reported as an adverse event. TEAEs were events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period extending to 30 days after the last dose of study drug.

Pyrexia

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1	± 0.56
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0	± 0.70
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	1	± 0.29

Sinus tachycardia

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities Recorded as Adverse Events (AEs) Primary · From start of study drug administration until 30 days after the last dose of study drug

AEs observed in participants with clinically significant ECG abnormalities were assessed.

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs) Primary · From start of study drug administration until 30 days after the last dose of study drug

An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent were events between first dose of study drug and 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with grade 3 or higher treatment-emergent adverse events for laboratory abnormalities were reported as clinically relevant laboratory changes.

Hemoglobin decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	3
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	1

Platelet count decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	2
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	1

Neutrophil count decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	2
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Lymphocyte count decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

White blood cell count decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Neutropenia

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Febrile neutropenia

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Blood albumin decreased

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	2

Number of Participants With Objective Response Rate (ORR): Complete Response (CR) or Partial Response (PR) Primary · Up to 2 years of post-treatment follow-up

Objective response rate defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria.

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Best Overall Objective Tumor Response Primary · Up to 2 years of post-treatment follow-up

Antitumor activity was assessed by best overall objective tumor response.

Complete response (CR)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Partial Response (PR)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0

Stable Disease (SD)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	2
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	3
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	2

Progressive Disease (PD)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	3

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Moxetumomab Pasudotox Primary · Predose, 0.25 (During Infusion), 0.5 (End of Infusion), 1, 1.5, 2, 4, 8 and 12 hours postdose on Day 1 and 5; Predose and End of Infusion on Day 3

The Tmax is the time to reach maximum observed plasma concentration of Moxetumomab Pasudotox.

Cycle 1, Day 1 (n=3,3,5)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0.50	0.500 – 0.500
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.00 – 0.500

Cycle 1, Day 5 (n=3,3,5)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0.500	0.300 – 0.500
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.300 – 1.00

Cycle 2, Day 1 (n=2,2,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	4.25	0.500 – 8.00
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0.375	0.250 – 0.500
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500

Cycle 2, Day 5 (n=2,2,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0.800	0.500 – 1.00
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500

Cycle 3, Day 1 (n=1,1,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500

Cycle 3, Day 5 (n=1,1,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	2.00	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	0.500	0.500 – 0.500

Cycle 4, Day 1 (n=1,NA,NA)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	NA	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	NA	NA – NA

Cycle 4, Day 5 (n=1,NA,NA)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0.500	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	NA	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	NA	NA – NA

Maximum Observed Serum Concentration (Cmax) for Moxetumomab Pasudotox Primary · Predose, 0.25 (During Infusion), 0.5 (End of Infusion), 1, 1.5, 2, 4, 8 and 12 hours postdose on Day 1 and 5; Predose and End of Infusion on Day 3

The Cmax is the maximum observed plasma concentration of Moxetumomab Pasudotox.

Cycle 1, Day 1 (n=3,3,5)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	97	59.1 – 107
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	57.7	46.5 – 145
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	180	63.7 – 351

Cycle 1, Day 5 (n=3,3,5)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	80.9	56.4 – 122
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	117	44.7 – 166
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	206	108 – 353

Cycle 2, Day 1 (n=2,2,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	94.0	66.0 – 122
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	723	146 – 1300
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	156	134 – 178

Cycle 2, Day 5 (n=2,2,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	50.5	0.00 – 101
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	80.8	72.3 – 89.2
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	211	171 – 250

Cycle 3, Day 1 (n=1,1,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	107	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	154	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	160	63.9 – 257

Cycle 3, Day 5 (n=1,1,2)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	93.4	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	200	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	266	156 – 376

Cycle 4, Day 1 (n=1,NA,NA)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	84.9	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	NA	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	NA	NA – NA

Cycle 4, Day 5 (n=1,NA,NA)

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	86.2	NA – NA
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	NA	NA – NA
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	NA	NA – NA

Number of Participants With Positive Neutralizing Antibodies Secondary · Up to end of treatment (4-6 weeks after the last dose)

Participants tested for immunogenicity to moxetumomab pasudotox prior to enrollment, before each cycle and at end of study. The neutralization assay measures the capacity of participant's plasma (antibodies) to inhibit the binding of moxetumomab pasudotox to its target, cluster of differentiation 22 (CD22), coated onto enzyme linked immunosorbent assay (ELISA) plates. It was used as a direct surrogate for biological activity based on the mechanism of action of this drug. Significant level of neutralizing antibody activity defined as the capacity of test plasma to inhibit greater than (\>)50 pe

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	0
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	1

Percentage Change From Baseline in Cluster of Differentiation 22 (CD22) Expression Secondary · End of treatment (4-6 weeks after the last dose)

Participants demonstrated CD22 expression on malignant cells at Screening and CD22 is a regulatory molecule that prevents the over activation of the immune system and the development of autoimmune diseases.

CD22-PE [OF CD5+/CD19+]

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	-33.65	± 27.79
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	-10.25	± 16.05
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	-8.85	± 16.19

(MESF CD22-PE [of CD5+/CD19+])

Group	Value	95% CI
CAT-8015 5 Microgram Per Kilogram (mcg/kg)	1139	± 1514.6
CAT-8015 10 Microgram Per Kilogram (mcg/kg)	-3076	± 5982.1
CAT-8015 20 Microgram Per Kilogram (mcg/kg)	-342.8	± 1816.8

Adverse events — posted to ClinicalTrials.gov

Time frame: From start of study drug administration until 30 days after the last dose of study drug. Reporting threshold: 1%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

CAT-8015 5 Microgram Per Kilogram (mcg/kg)

Serious: 1/3 (33%)

Deaths: —

CAT-8015 10 Microgram Per Kilogram (mcg/kg)

Serious: 2/3 (67%)

Deaths: —

CAT-8015 20 Microgram Per Kilogram (mcg/kg)

Serious: 3/5 (60%)

Deaths: —

Serious adverse events (10 terms)

Reaction	System	CAT-8015 5 Microgram Per K…	CAT-8015 10 Microgram Per …	CAT-8015 20 Microgram Per …
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—
Optic ischaemic neuropathy	Eye disorders	—	—	—
Acute pulmonary histoplasmosis	Infections and infestations	—	—	—
Infection	Infections and infestations	—	—	—
Neutropenic infection	Infections and infestations	—	—	—
Pneumonia	Infections and infestations	—	—	—
Blood calcium increased	Investigations	—	—	—
Tumour lysis syndrome	Metabolism and nutrition disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Obstructive airways disorder	Respiratory, thoracic and mediastinal disorders	—	—	—

Other adverse events (70 terms — click to expand)

Reaction	System	CAT-8015 5 Microgram Per K…	CAT-8015 10 Microgram Per …	CAT-8015 20 Microgram Per …
Haemoglobin decreased	Investigations	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Blood albumin decreased	Investigations	—	—	—
Blood glucose increased	Investigations	—	—	—
Blood magnesium decreased	Investigations	—	—	—
Neutrophil count decreased	Investigations	—	—	—
Platelet count decreased	Investigations	—	—	—
Hyperuricaemia	Metabolism and nutrition disorders	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—
Vision blurred	Eye disorders	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—
Gingival pain	Gastrointestinal disorders	—	—	—
Oral pain	Gastrointestinal disorders	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—
Chills	General disorders	—	—	—
Fatigue	General disorders	—	—	—
Localised oedema	General disorders	—	—	—
Oedema	General disorders	—	—	—
Oedema peripheral	General disorders	—	—	—
Pain	General disorders	—	—	—
Pyrexia	General disorders	—	—	—
Cystitis	Infections and infestations	—	—	—
Histoplasmosis	Infections and infestations	—	—	—
Rhinitis	Infections and infestations	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—
Blood glucose decreased	Investigations	—	—	—
Blood magnesium increased	Investigations	—	—	—
Blood phosphorus decreased	Investigations	—	—	—
Blood potassium decreased	Investigations	—	—	—
Blood sodium decreased	Investigations	—	—	—
Blood sodium increased	Investigations	—	—	—

Most-reported serious reactions: Febrile neutropenia, Optic ischaemic neuropathy, Acute pulmonary histoplasmosis, Infection, Neutropenic infection, Pneumonia, Blood calcium increased, Tumour lysis syndrome.

Data from ClinicalTrials.gov NCT00587457 adverse events section.

Sponsor's own description

This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
Lin AY, Dinner SN. · · 2019 · cited 35× · PMID 31594764 · DOI 10.1182/bloodadvances.2019000507
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
Barreca M, Lang N, Tarantelli C, Spriano F, et al · · 2022 · cited 23× · PMID 36654819 · DOI 10.37349/etat.2022.00112

Verify or expand the search:

Other MedImmune LLC trials

Trials by the same sponsor.

NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00587457 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
Last refreshed: 6 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00587457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT00587457

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (10 terms)

Sponsor's own description

Publications & conference data

Related trials

Other MedImmune LLC trials

Verify against primary sources